Dr. Nabil Noureddin, MD

Dr. Noureddin practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Noureddin's NPI, 1972037026, was assigned on April 15, 2017. Dr. Noureddin graduated from University of Aleppo Faculty of Medicine in 2012. Dr. Noureddin's California license number on file is A167156.

Dr. Noureddin's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Noureddin's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Noureddin to 2 more clinical labs, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Noureddin practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Noureddin's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Noureddin is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Noureddin's licenses on file in 2 states: California and Nevada.

CMS data shows 167 Medicare services from Dr. Noureddin across 7 procedure codes in 2024, for 147 Medicare patients. Medicare paid $21,271 for them.

CMS counts 147 Medicare patients who saw Dr. Noureddin in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Noureddin's median patient age at 58, with 55% women.

In 2024, Dr. Noureddin wrote 142 Medicare Part D claims for 104 patients. 82% of them were for generic drugs. CMS names the drug for 86 of them, across 4 drugs with 11 or more claims each, at $2,683 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Noureddin for performance year 2024, reported as part of a group. Dr. Noureddin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 21 papers to Dr. Noureddin, published from 2014 to 2024. 2023 was the busiest year, with 6. The most frequent topics are Non-alcoholic Fatty Liver Disease, Liver Cirrhosis and Diabetes Mellitus, Type 2. Dr. Noureddin has published most often in Aliment Pharmacol Ther. Dr. Noureddin's most frequent co-authors are Mazen Noureddin, MD, Rohit Loomba, MD and Veeral Haresh Ajmera, MD.

CMS Open Payments shows 87 general payments to Dr. Noureddin from 14 drug and device companies from 2018 to 2025. Grants make up the largest share, 65% of the total. Boston Scientific Corporation paid the most, $15,895.

Dr. Noureddin graduated from University of Aleppo Faculty of Medicine in 2012.

Dr. Noureddin is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.